Sangamo Therapeutics, Inc. (SGMO)

Sangamo Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	38.34	41.92	45.2	100.44	178.87	131.33
Short-Term Investments	-	-	35.8	177.19	197.68	510.09
Cash & Short-Term Investments	38.34	41.92	81	277.63	376.55	641.42
Cash Growth	38.00%	-48.25%	-70.82%	-26.27%	-41.30%	76.96%
Accounts Receivable	0.37	0.53	0.92	3.68	6.01	5.22
Other Receivables	4.6	4.07	3.14	0.79	0.35	1.04
Receivables	4.98	4.6	4.07	4.47	6.36	6.26
Prepaid Expenses	6.57	5.18	9.26	18.22	15.86	11.99
Total Current Assets	49.89	51.69	94.33	300.33	398.77	659.67
Property, Plant & Equipment	30.79	34.76	52.87	125.53	124.7	112.37
Long-Term Investments	-	-	-	29.85	88.17	50.53
Goodwill	-	-	-	37.55	39.7	42.8
Other Intangible Assets	-	-	-	50.73	53.76	58.13
Long-Term Deferred Tax Assets	-	-	-	1.12	1.06	0.47
Other Long-Term Assets	16.87	15.19	18.13	17.41	15.76	14.58
Total Assets	97.56	101.64	165.32	562.51	721.92	938.55
Accounts Payable	10.74	15.49	15.26	22.42	9.76	12.55
Accrued Expenses	29.36	17.56	16.15	33.39	28.39	30.66
Current Portion of Leases	-	4.31	4.59	4.12	4.03	3.69
Current Unearned Revenue	7.56	7.56	-	51.78	85.71	91.64
Other Current Liabilities	-	0.9	11.73	-	-	5
Total Current Liabilities	47.66	45.81	47.73	111.71	127.89	143.55
Long-Term Leases	23.46	26.25	33.52	38.99	44.06	38.4
Long-Term Unearned Revenue	5.87	5.87	-	109.38	166.78	245.05
Long-Term Deferred Tax Liabilities	-	-	-	6.27	6.65	7.19
Other Long-Term Liabilities	0.96	0.93	1.19	1.21	1.22	7.01
Total Liabilities	77.96	78.87	82.43	267.55	346.58	441.18
Common Stock	2.73	2.13	1.78	1.67	1.46	1.42
Additional Paid-In Capital	1,573	1,532	1,492	1,450	1,334	1,269
Retained Earnings	-1,555	-1,504	-1,406	-1,149	-956.27	-777.98
Comprehensive Income & Other	-1.46	-7.53	-4.6	-8.4	-3.99	5.42
Total Common Equity	19.6	22.77	82.89	294.96	375.34	498.23
Minority Interest	-	-	-	-	-	-0.87
Shareholders' Equity	19.6	22.77	82.89	294.96	375.34	497.37
Total Liabilities & Equity	97.56	101.64	165.32	562.51	721.92	938.55
Total Debt	23.46	30.57	38.1	43.11	48.08	42.09
Net Cash (Debt)	14.88	11.35	42.9	264.37	416.64	649.87
Net Cash Growth	-	-73.54%	-83.77%	-36.55%	-35.89%	91.19%
Net Cash Per Share	0.07	0.06	0.25	1.71	2.88	4.83
Filing Date Shares Outstanding	301.71	224.71	178.91	168.48	145.97	143.25
Total Common Shares Outstanding	272.8	212.84	178.13	166.79	145.92	142.06
Working Capital	2.23	5.89	46.6	188.62	270.88	516.12
Book Value Per Share	0.07	0.11	0.47	1.77	2.57	3.51
Tangible Book Value	19.6	22.77	82.89	206.68	281.88	397.31
Tangible Book Value Per Share	0.07	0.11	0.47	1.24	1.93	2.80
Machinery	-	32.78	47.02	54.72	49.85	30.7
Construction In Progress	-	-	1.09	14.77	4.73	12.09
Leasehold Improvements	-	24.92	29.81	30.57	21.97	15.95

Updated May 12, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q